MSL-KOL Engagement: Measuring Success

1
MSL-KOL Engagement Measuring SuccessMarket
Research Reports Distributor - Aarkstore.com have
vast database on market research reports, company
financials, company profiles, SWOT analysis,
company report, company statistics, strategy
review, industry report, industry research to
provide excellent and innovative service to our
report buyers.Aarkstore.com have very
interactive search feature to browse across more
than 2,50,000 business industry reports. We are
built on the premise that reading is valuable,
capable of stirring emotions and firing the
imagination. Whether you're looking for new
market research report product trends or
competitive industry analysis of a new or
existing market, Aarkstore.com has the best
resource offerings and the expertise to make sure
you get the right product every time.
2
MSL-KOL Engagement Measuring Success

• Its difficult to quantify. Its role
  constantly changes. And despite all efforts to
  gain transparency, the field of medical science
  liaison (MSL) remains an elusiveseemingly
  immeasurableyet undeniable value-added role in
  the pharmaceutical industry.In this latest
  report, FirstWord Dossier tackles the intangible
  nature of MSL work to describe not only the
  obstacles to identifying appropriate,
  attributable and transparent metrics, but how to
  develop them so that they align with corporate
  objectives.Report OverviewWhile contributing
  significantly to company success, quantifying
  what MSLs do has always proven elusive. In MSL
  Metrics Measuring Success, FirstWord unravels
  the subtle impact of the MSL field force. The
  report reviews the main quantitative and
  qualitative metrics used to measure achievement,
  offers insight into how MSLs specialiseand the
  drawbacks that may representand examines the
  structure of successful MSL programmes. Concisely
  written, the report offers the industry
  clear-sighted, practical strategies for creating
  a solid approach to measuring MSL success.Key
  Report FeaturesDiscussion of the evolution of
  the MSL role and their relationships with
  researchers, payers and governmentFeedback from
  KOLs on what they want from MSLsDiscussion of
  generic versus targeted metricsData on the main
  quantitative and qualitative metrics used by
  industryThe pros and cons of MSL field force
  specialisationHow to align MSL metrics with
  corporate and medical affairs objectives

3

• Who Would Benefit From This Report?Medical and
  scientific affairs managersGlobal medical
  affairs managersSales and marketing
  managersProfessional and medical science liaison
  officersKey account and territory
  managersCommunications and technology support
  teamsHealth outcomes managersExpert
  ViewsJane Chin, founder of the MSL Institute
  and managing partner of 9PillarsEric Kassel,
  senior scientific medical director,
  AllerganAndrew Lam, senior MSL, Shire Human
  Genetic TherapiesDoral Fredericks, head of
  medical affairs, ISTA PharmaceuticalsAshok
  Bhaseen, head of sales and marketing,
  PediaPharmDr Robin Winter-Sperry, president and
  CEO, Scientific AdvantageCameron Tew, director,
  Best Practices LLCDrew Macgregor, medical
  operations manager, Bristol-Myers Squibb
  EuropeVice-president of Medical and Scientific
  Affairs, Company AKey QuotesA company will
  never say, because of the MSL, the sales team
  have gotten this much market share because the
  FDA doesnt look kindly on that. But that doesnt
  mean it doesnt happen. There are companies that
  will use MSLs very heavily to support the sales
  force. Jane Chin, founder, MSL Institute and
  managing partner of 9PillarsNobody really
  knows of a good way to do MSL metrics. We dont
  want to use the same metrics as the sales
  organisation, but how do we measure MSL success
  without being able to have defined outcomes? 
  Doral Fredericks, vice-president, Medical
  Affairs, at specialty company, ISTA
  Pharmaceuticals

4
Nobody in MSL land leadership likes to
hear it, but you have to customise the data for
what your stakeholders want. Whos asking for the
value? What do they think the value is? What are
they looking for to see value? Then you have to
fill that with numbers and thats how you report
it on a quarterly or whatever basis.  Eric
Kassel, vice-president of global medical affairs,
UCBKey BenefitsExpert insight from key players
in medical affairs on the most appropriate and
effective metricsPractical tips for measuring
quantitative and qualitative resultsAccess to
the MSL perspective, case studies and building
effective MSL programmes
5

• MSL programmesCase study Showing internal
  valueBuilding blocksWhat data needs to be
  captured?Development plansFrequency of
  visitsVersatilityCapacity planningReactive
  workChanging company needsThe scorecardThe
  MSL perspectiveCareer progressionScientific
  voice of a companyAcknowledgements

• Executive summaryMSLs are not sales repsEyes
  and ears of the companyA diversifying
  roleIncreased competition to engage with
  KOLsInadequate metrificationMeasuring MSL
  successCounting numbersQuantitative
  metricsQualitative metricsThe language of
  numbersSatisfying internal stakeholdersConstant
  adjustmentsMaking sense of the numbersHow MSLs
  are deployedAreas of specialisationMSLs in
  clinical researchEngaging payersGovernment
  affairsSpecialisation versus flexibilityIs
  therapeutic specialisation necessary?Segmenting
  KOLsWeeding out the good from the badTailoring
  the metrics

6

• Related Reports
• United Arab Emirates In Vitro Diagnostics
  Investment Opportunities, Analysis and Forecasts
  to 2018Chile In Vitro Diagnostics Investment
  Opportunities, Analysis and Forecasts to 2018
• Norway In Vitro Diagnostics Investment
  Opportunities, Analysis and Forecasts to 2018
• Ireland In Vitro Diagnostics Investment
  Opportunities, Analysis and Forecasts to 2018
• Greece In Vitro Diagnostics Investment
  Opportunities, Analysis and Forecasts to 2018
• Hungary In Vitro Diagnostics Investment
  Opportunities, Analysis and Forecasts to 2018
• Poland In Vitro Diagnostics Investment
  Opportunities, Analysis and Forecasts to 2018
• Portugal In Vitro Diagnostics Investment
  Opportunities, Analysis and Forecasts to 2018
• Switzerland In Vitro Diagnostics Investment
  Opportunities, Analysis and Forecasts to 2018
• Turkey In Vitro Diagnostics Investment
  Opportunities, Analysis and Forecasts to 2018

7

• Contact Us
• Aarkstore Enterprise
• Tel [phone]
• Mobile No08149852585
• Email contact_at_aarkstore.com
• Website http//www.aarkstore.com
• Blog http//www.emarketreports.com
• http//teju-aarkstoreenterprise.blogspot.in
• Follow us on twitter http//twitter.com/aarkstore
  dotcom
• http//in.linkedin.com/in/aarkstore
• http//www.facebook.com/aarkstoreenterprise